BIOVIE INC. (BIVIW) — Quarterly Report

AI-Powered SEC Filing Analysis

Latest Quarterly Report Filed: 2026-05-11

Key Insights

The filing is dated 2026-05-11 for Q3 fiscal year ending 2026-03-31, indicating BioVie is reporting on a nine-month period (2025-07-01 to 2026-03-31), suggesting potential fiscal year restructuring or extended reporting period.
The document structure shows extensive tracking of equity instruments including common stock, warrants, stock options, and RSUs across multiple reporting periods, indicating significant equity-based compensation activity and potential dilution considerations.
The presence of a Long COVID Program as a tracked segment suggests this is a material business focus area, with specific financial tracking from 2024-2026, indicating ongoing clinical or commercial development in this therapeutic area.

Want the newest filings?

This analysis covers the filing from 2026-05-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Quarterly Report filings

Filed: 2026-02-06

The company reported a significant increase in cash and short-term investments, indicating strong liquidity and the ability to fund ongoing operations.
The company has been actively granting stock options and restricted stock units to its employees, suggesting a focus on retaining and incentivizing key talent.
The company appears to have made some recent changes to its warrant agreements, which may impact the dilution of existing shareholders.

Other reports for BIOVIE INC.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.